Patent application number | Description | Published |
20090035298 | METHODS TO TREAT ALZHEIMER'S DISEASE OR OTHER AMYLOID BETA ACCUMULATION ASSOCIATED DISORDERS - The present invention provides methods for treating amyloid-beta accumulation-associated disorders, such as Alzheimer's disease. The methods comprise modulating the concentration of amyloid-beta in the brain interstitial fluid. In particular, the methods comprise modulating the activity of corticotrophin-releasing factor (CRF), which in turn modulates the concentration of amyloid-beta. | 02-05-2009 |
20090142766 | METHODS FOR MEASURING THE METABOLISM OF CNS DERIVED BIOMOLECULES IN VIVO - The present invention provides methods for measuring the metabolism of a central nervous system derived biomolecule implicated in a neurological and neurodegenerative disease or disorder. In particular, the method comprises measuring the in vivo metabolism of the biomolecule in the central nervous system of a subject. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. | 06-04-2009 |
20090263829 | ALZHEIMER'S DISEASE BIOMARKERS AND METHODS OF USE - The invention encompasses biomarkers for AD, a method for detecting AD, a method of monitoring AD, and a kit for quantifying biomarkers for AD. | 10-22-2009 |
20090264355 | METHODS TO TREAT ALZHEIMER'S DISEASE OR OTHER DISORDERS MEDIATED BY AMYLOID-BETA ACCUMULATION IN A SUBJECT - The invention provides methods of delaying the onset, slowing the progression, preventing, or treating Alzheimers disease in a subject. In particular, the invention provides methods of modulating transport of Aβ across the blood brain barrier of the subject. | 10-22-2009 |
20110143380 | ALZHEIMER'S DISEASE BIOMARKERS AND METHODS OF USE - The invention encompasses biomarkers for AD, a method for detecting AD, a method of monitoring AD, and a kit for quantifying biomarkers for AD. | 06-16-2011 |
20110177509 | RISK FACTORS AND A THERAPEUTIC TARGET FOR NEURODEGENERATIVE DISORDERS - Compositions and methods for detecting a neurodegenerative disorder, and methods of treating a neurogenerative disorder are disclosed. Biomarkers for a neurodegenerative disorder containing a polymorphism in the nucleotide sequence of PP3R1, GSK3beta, PPP3CA, FYN, WISP1, MGEA5, CTSD, F2, MAPT, OGT or PRKCA are also disclosed. A method for detecting a neurodegenerative disorder by detecting polymorphisms in the above genes is further disclosed. | 07-21-2011 |
20140037638 | COMPOSITIONS AND METHODS FOR TREATING AMYLOID PLAQUE ASSOCIATED SYMPTOMS - The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque associated symptoms or for decreasing amyloid plaque loads. The method comprises administering an effective amount of an anti-ApoE antibody to a living mammalian biosystem such as to a human. | 02-06-2014 |
20140370619 | METHODS FOR DIAGNOSING ALZHEIMER'S DISEASE - The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for Aβ amyloidosis, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided. | 12-18-2014 |
20140377319 | ALTERING PROTEIN CONCENTRATIONS IN CEREBROSPINAL FLUID AND/OR BRAIN INTERSTITIAL FLUID - Devices and methods of altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid are disclosed. Devices include a support having at least one protease attached to the support. The device may further include a housing. Devices may be implantable for use in an in vivo active flow system or for use in an in vivo passive system. Devices may also be used in an ex vivo active flow system. Devices may also be used in a passive system to treat cerebrospinal fluid and/or brain interstitial fluid that is withdrawn, or in a passive system that is implanted surgically. Methods include contacting cerebrospinal fluid and/or brain interstitial fluid with a support including at least one protease attached to the support. Proteins contained in the cerebrospinal fluid and/or brain interstitial fluid are cleaved by the protease resulting in the reduction of protein in cerebrospinal fluid and/or brain interstitial fluid. Additionally, methods are disclosed for treating neurodegenerative diseases and neurological disorders. | 12-25-2014 |